Exercise modulates platelet-nasopharyngeal carcinoma cell aggregation and subsequent tissue factor and matrix metalloproteinase activities.
Interaction between platelet and carcinoma cell contributes to pathogenesis of cancer-related thrombosis and metastasis. This study investigated whether physical exercise affects platelet-nasopharyngeal carcinoma cell (NPC) interaction and platelet-promoted tissue factor (TF) and matrix metalloproteinase (MMP) activities of NPC. Thirty sedentary men performed on three occasions moderate-intensity exercise [MIE, 60% maximal oxygen consumption (V(.)o(2max)) for 40 min] and high-intensity exercise (HIE, up to V(.)o(2max)), with and without warm-up exercise (WUE, 60% V(.)o(2max) for 20 min) on a bicycle ergometer. Before and immediately after exercise, platelet-NPC aggregation, the TF, MMP-2 and MMP-9 expressions and activities, and TF pathway inhibitor (TFPI) and tissue inhibitor of MMP-1 levels of NPC and platelet were measured. The results of this study demonstrated that HIE enhanced platelet-NPC aggregation in the presence of fibrinogen and was accompanied by increased platelet-promoted TF activity, expression of NPC, decreased platelet-promoted MMP-2 and MMP-9 activities, and TFPI release of NPC, whereas these alterations to HIE on platelet-NPC interactions were ameliorated by WUE pretreatment. Conversely, MIE reduced the formation of platelet-NPC aggregates, but did not change the TF, TFPI, MMP-2, MMP-9, tissue inhibitor of MMP activities, and/or levels of NPC mediated by platelet. It is concluded that HIE may enhance aggregation and coagulation and reduce MMP bioactivity related to platelet-NPC interactions, by raising the binding affinity to fibrinogen and TF activity and expression and lowering TFPI release and MMP-2 and -9 activities. These effects on HIE diminish after WUE. However, MIE minimizes the risk of thrombosis induced by platelet-NPC interactions.
Wang
Jong-Shyan
JS
Graduate Institute of Rehabilitation Science, Chang Gung University, 259 Wen-Hwa 1st Rd., Kwei-Shan, Tao-Yuan 333, Taiwan. s5492@mail.cgu.edu.tw
Chang
Chuen-Ying
CY
Chow
Shu-Er
SE
Chen
Yu-Wen
YW
Yang
Chuen-Mao
CM
D000328:Adult; D001792:Blood Platelets / Q000378:metabolism / Q000502:physiology*; D002277:Carcinoma / Q000150:complications / Q000503:physiopathology*; D002449:Cell Aggregation / Q000502:physiology; D015444:Exercise / Q000502:physiology*; D006801:Humans; D008074:Lipoproteins / Q000378:metabolism; D008297:Male; D020778:Matrix Metalloproteinase 2 / Q000378:metabolism; D020780:Matrix Metalloproteinase 9 / Q000378:metabolism; D009303:Nasopharyngeal Neoplasms / Q000150:complications / Q000503:physiopathology*; D009362:Neoplasm Metastasis / Q000517:prevention & control*; D013925:Thromboplastin / Q000378:metabolism; D013927:Thrombosis / Q000209:etiology* / Q000517:prevention & control; D019715:Tissue Inhibitor of Metalloproteinase-1 / Q000378:metabolism
D008074:Lipoproteins; D019715:Tissue Inhibitor of Metalloproteinase-1; C051928:lipoprotein-associated coagulation inhibitor; D013925:Thromboplastin; D020778:Matrix Metalloproteinase 2; D020780:Matrix Metalloproteinase 9